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The candidate-gene approach in association studies of polygenic diseases has often yielded conﬂicting results. In
this hospital-based case-control study with 696 white patients newly diagnosed with bladder cancer and 629
unaffected white controls, we applied a multigenic approach to examine the associations with bladder cancer risk
of a comprehensive panel of 44 selected polymorphisms in two pathways, DNA repair and cell-cycle control, and
to evaluate higher-order gene-gene interactions, using classiﬁcation and regression tree (CART) analysis. Individually,
only XPD Asp312Asn, RAG1 Lys820Arg, and a p53 intronic SNP exhibited statistically signiﬁcant main effects.
However, we found a signiﬁcant gene-dosage effect for increasing numbers of potential high-risk alleles in DNA-
repair and cell-cycle pathways separately and combined. For the nucleotide-excision repair pathway, compared with
the referent group (fewer than four adverse alleles), individuals with four (odds ratio [OR]p 1.52, 95% CI 1.05–
2.20), ﬁve to six (OR p 1.81, 95% CI 1.31–2.50), and seven or more adverse alleles (ORp 2.50, 95% CI 1.69–
3.70) had increasingly elevated risks of bladder cancer (P for trend !.001). Each additional adverse allele was
associated with a 1.21-fold increase in risk (95% CI 1.12–1.29). For the combined analysis of DNA-repair and
cell-cycle SNPs, compared with the referent group (!13 adverse alleles), the ORs for individuals with 13–15, 16–
17, and 18 adverse alleles were 1.22 (95% CI 0.84–1.76), 1.57 (95% CI 1.05–2.35), and 1.77 (95% CI 1.19–
2.63), respectively (P for trendp .002). Each additional high-risk allele was associated with a 1.07-fold signiﬁcant
increase in risk. In addition, we found that smoking had a signiﬁcant multiplicative interaction with SNPs in the
combined DNA-repair and cell-cycle–control pathways ( ). All genetic effects were evident only in “everP ! .01
smokers” (persons who had smoked 100 cigarettes) and not in “never smokers.” A cross-validation statistical
method developed in this study conﬁrmed the above observations. CART analysis revealed potential higher-order
gene-gene and gene-smoking interactions and categorized a few higher-risk subgroups for bladder cancer.Moreover,
subgroups identiﬁed with higher cancer risk also exhibited higher levels of induced genetic damage than did
subgroups with lower risk. There was a signiﬁcant trend of higher numbers of bleomycin- and benzo[a]pyrene
diol-epoxide (BPDE)–induced chromatid breaks (by mutagen-sensitivity assay) and DNA damage (by comet assay)
for individuals in higher-risk subgroups among cases of bladder cancer in smokers. The P for the trend was .0348
for bleomycin-induced chromosome breaks, .0036 for BPDE-induced chromosome breaks, and .0397 for BPDE-
induced DNA damage, indicating that these higher-order gene-gene and gene-smoking interactions included SNPs
that modulated repair and resulted in diminished DNA-repair capacity. Thus, genotype/phenotype analyses support
ﬁndings from CART analyses. This is the ﬁrst comprehensive study to use a multigenic analysis for bladder cancer,
and the data suggest that individuals with a higher number of genetic variations in DNA-repair and cell-cycle–
control genes are at an increased risk for bladder cancer, conﬁrming the importance of taking a multigenic pathway-
based approach to risk assessment.
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The candidate-gene approach is hypothesis driven, uses
a priori knowledge of SNP and gene functions, and has
yielded sometimes informative but often conﬂicting data
in cancer association studies. In many studies where a
signiﬁcant association is reported, the odds ratios (ORs)
for individual variants are !2 (Goode et al. 2002; Neu-
mann et al. 2005). There are innumerable instances in
which association studies have been unable to replicate
an initial positive candidate-gene ﬁnding. Among the
reasons for this lack of replication are small sample size,
inadequate statistical methods, and failure to evaluate
the effect of multiple pathophysiologically related genes
(Horne et al. 2005). The low risk conferred by an in-
dividual polymorphism is not surprising, given that car-
cinogenesis is usually a multistep, multigenic process,
and it is unlikely that any one single genetic polymor-
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phism would have a dramatic effect on cancer risk.
Therefore, single-gene studies are likely to provide lim-
ited value in predicting risk. A pathway-based genotyp-
ing approach, which assesses the combined effects of a
panel of polymorphisms that interact in the same path-
way, may amplify the effects of individual polymor-
phisms and enhance the predictive power. Several recent
small-scale multigenic studies provide evidence of the
promising potential of applying such a pathway-based
multigenic approach in association studies (Han et al.
2004; Popanda et al. 2004; Cheng et al. 2005; Gu et al.
2005). In this article, we use bladder cancer as the cancer
prototype and focus on two relevant physiologic path-
ways, DNA repair and cell-cycle control, to illustrate
our theme.
Bladder cancer is the malignancy with the ﬁfth highest
incidence in the United States, with ∼63,210 new cases
in 2005 (Jemal et al. 2005). Cigarette smoking is the
predominant risk factor and is estimated to be respon-
sible for half the cases in men and for a third in women.
Occupational exposure to carcinogens is the second ma-
jor risk factor. Despite the overwhelming evidence that
most bladder cancers are attributable in part to envi-
ronmental carcinogenic exposures, only a fraction of ex-
posed individuals actually develop bladder cancer, and
the working hypothesis is that there are also predispos-
ing genetic factors (Shields and Harris 2000; Wu et al.
2004).
DNA damage repair and cell-cycle checkpoints are
two primary defense mechanisms against mutagenic ex-
posures. There are four major DNA-repair pathways in
human cells: mismatch repair, nucleotide-excision repair
(NER), base-excision repair (BER), and double-strand–
break (DSB) repair (Christmann et al. 2003). The NER
pathway mainly removes bulky DNA adducts typically
generated from exposure to polycyclic aromatic hydro-
carbons in tobacco smoke. The BER pathway is re-
sponsible for removal of oxidized DNA bases that may
arise endogenously or from exogenous agents. The DSB
pathway is responsible for repairing double-strand
breaks caused by a variety of exposures, including ion-
izing radiation, free radicals, and telomere dysfunction.
There are two distinct and complementary pathways for
DSB repair—namely, homologous recombination (HR)
and nonhomologous end joining (NHEJ). Cell-cycle
checkpoints are regulatory pathways that control the
order and timing of cell-cycle transitions to ensure the
ﬁdelity of critical events such as DNA replication and
chromosome segregation (Elledge 1996). Cells may be
arrested at any of the checkpoints, temporarily halting
the cell cycle and allowing DNA repair to be completed.
Checkpoint loss and perturbation of cell-cycle control
results in genomic instability and is a hallmark of cancer,
as evidenced by the frequent inactivation of cell-cycle–
control genes, including p53, p16, and Rb, in various
cancers (Hanahan and Weinberg 2000).
There is considerable interindividual variation in
DNA-repair capacity (DRC) and strong evidence that
reduced DRC is associated with increased cancer risk
(Berwick and Vineis 2000; Spitz et al. 2003; Wu et al.
2004). Polymorphisms in DNA-repair genes are hy-
pothesized to be a contributor to this individual DRC
variation (Mohrenweiser et al. 2003). There have been
numerous studies, often with conﬂicting results, assess-
ing the associations of polymorphisms in DNA-repair
and cell-cycle genes with cancer risk on the basis of the
hypothesis that individuals with “adverse” genotypes
that result in reduced DRC or perturbed cell-cycle con-
trol are at a higher risk of developing cancer than the
general population (Goode et al. 2002; Wu et al. 2004;
Neumann et al. 2005).
In this study, we applied a pathway-based multigenic
approach to examine the associations of a comprehen-
sive panel of polymorphisms in DNA-repair and cell-
cycle genes with bladder cancer risk. We selected 13
SNPs from the NER pathway, 8 SNPs from the BER
pathway, 8 SNPs from the HR pathway, 5 SNPs from
the NHEJ pathway, and 10 SNPs from the cell-cycle–
control pathway. The majority of these SNPs were se-
lected from published association studies, and a fewwere
chosen from dbSNP on the basis of their location (pro-
moter or coding regions) and minor-allele frequencies
(15%). To our knowledge, this is the largest multigenic
cancer association study reported. We examined the
combined effects of the minor alleles and evaluated
higher-order gene-gene interactions, using several statis-
tical models. In addition, we used two functional assays
assessing genetic instability to determine genotype-phe-
notype correlations, in an attempt to validate our an-
alytic approach. This pathway-based multigenic ap-
proach may provide a reﬁnement of epidemiologic
proﬁles associated with risk.
Material and Methods
Study Subjects
This study included patients with newly diagnosed bladder
cancer and age-, gender-, and ethnicity-matched control sub-
jects. The cases were enrolled at The University of Texas M.
D. Anderson Cancer Center and the Scott Department of Urol-
ogy at Baylor College of Medicine between 1999 and 2003.
All patients had histopathologically conﬁrmed bladder cancer,
and none had received chemotherapy or radiation before en-
rollment. The control subjects were healthy individuals with
no prior history of cancer (except nonmelanoma skin cancer)
who were recruited from Kelsey Seybold, the largest multis-
pecialty, managed-care physician group in the Houston met-
ropolitan area. We also excluded control subjects with chronic
urinary tract disease, obstructive airway disease, and diabetes.
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Control subjects were matched to the case patients by age (5
years), sex, and ethnicity. The potential control subjects were
ﬁrst surveyed with a short questionnaire to elicit willingness
to participate in the study and to provide preliminary demo-
graphic data for matching. A Kelsey-Seybold staff member
provided the questionnaire to each potential control subject
during clinical registration. The potential control subjects were
contacted by telephone at a later date to conﬁrm their will-
ingness to participate and to schedule an interview appoint-
ment at a Kelsey-Seybold clinic convenient to the participant.
Informed consent was obtained from all study participants
before the collection of epidemiological data and blood sam-
ples by trained M. D. Anderson staff interviewers. The re-
sponse rates were 75% for the controls and 92% for the cases.
Epidemiology Data Collection
In 45-min interviews, trained M. D. Anderson staff inter-
viewers collected data on demographics, smoking history, and
family history of cancer. At the end of the interviews, 40-mL
blood samples were drawn into coded heparinized tubes. In-
dividuals who had smoked at least 100 cigarettes in their life-
times were deﬁned as “ever smokers.” Participants who had
quit smoking at least 1 year before the study were categorized
as former smokers. All participants signed informed consent
agreements, and the institutional review boards of M. D. An-
derson, Baylor College ofMedicine, and Kelsey-SeyboldClinic,
in accordance with the U.S. Department of Health and Human
Services, approved the study.
Genotyping
Genomic DNA was extracted from peripheral blood lym-
phocytes by proteinase K digestion, followed by isopropanol
extraction and ethanol precipitation; DNA samples were
stored at80C. Genotyping was performed using the Taqman
method with a 7900 HT sequence detector system (Applied
Biosynthesis), except for XPA, XPD Asp312Asn, and p53 in-
tron 3 polymorphism, which were genotyped using PCR-RFLP
(Spitz et al. 2001; Wu et al. 2002, 2003). The primer and
probe sequences for each SNP are available upon request. Am-
pliﬁcation mixes (5 ml) contained sample DNA (5 ng), 1#
TaqMan buffer A, deoxynucleotide triphosphate (200 mM),
MgCl2 (5 mM), AmpliTaq Gold (0.65 units), each primer (900
nM), and each probe (200 nM). The thermal cycling conditions
consisted of 1 cycle for 10 min at 95C, 40 cycles for 15 s at
95C, and 40 cycles for 1 min at 60C. SDS version 2.1 soft-
ware (Applied Biosystems) was used to analyze end-point ﬂuo-
rescence, in accordance with the allelic discrimination tech-
nique. Water control, ample internal controls, and previously
genotyped samples were included in each plate to ensure ac-
curacy of the genotyping. Positive and negative controls were
used in each genotyping assay, and 5% of the samples were
randomly selected and run in duplicates with 100%
concordance.
Genetic Instability Index
Genetic instability was measured by two in vitro assays.
Mutagen sensitivity was assessed in vitro in lymphocyte cul-
tures by counting the number of chromatid breaks induced by
exposure to either bleomycin or benzo[a]pyrene diol-epoxide
(BPDE), as described elsewhere (Hsu et al. 1989; Wu et al.
1998a). In brief, blood cultures were incubated for 3 d and
then exposed to either bleomycin (0.03 U/mL) for 5 h or BPDE
(2 mM) for 24 h. Cells were harvested, and chromatid breaks
were counted in 50 metaphases per sample and were recorded
as the mean number of breaks per cell. Laboratory personnel
read the slides without knowledge of the individual’s cancer
status. The comet assay under alkaline conditions was per-
formed also as described elsewhere (Schabath et al. 2003). In
brief, blood cultures were challenged with 2 mM BPDE. Then,
the cell culture was mixed with agarose gel and was adhered
to a microscope slide. The cells were lysed by submersing the
slides in freshly prepared lysis buffer for 1 h at 4C to remove
all the cellular proteins. The slides were next placed in alkali
buffer (pH 112.0) to denature and unwind the DNA and to
expose the alkali-labile sites. The slides were subjected to elec-
trophoresis and were stained with ethidium bromide, then
were neutralized, were ﬁxed in 100% methanol, and were
stored in the dark at room temperature until ready for analysis.
Consecutive comet cells ( [25 cells from each end ofnp 50
the slide]) were manually selected and were automatically
quantiﬁed using the Komet 4.0.2 (Kinetic Imaging) imaging
software attached to a ﬂuorescent microscope. The Olive tail
moment was used as the parameter for DNA damage com-
puted by the imaging system software. The averages of the
Olive tail moment for each subject were calculated for the
baseline and mutagen-induced comets. All assays were per-
formed in a blinded manner, and a single lab technician per-
formed the entire procedure for each assay to minimize inter-
individual variation. Detailed scanning criteria for the comet
assay have also been well established to ensure consistency.
There were 877 samples with mutagen-sensitivity data and 957
samples with comet assay data. The functional assays started
during the second year of recruitment, and all the samples were
measured consecutively. There were no signiﬁcant differences
in characteristics between subjects with functional data and
those without functional data.
Statistical Analysis
The x2 and Fisher’s exact tests were used to assess patient
characteristics by genotype and to compare cases with controls.
Student’s t test was used to test for differences between the
cases and controls for continuous variables. ORs were cal-
culated as estimates of relative risk. Unconditional multivar-
iable logistic regression was performed to control for possible
confounding by age, sex, ethnicity, and smoking status, where
appropriate. Since we found no deﬁnitive prior associations in
our review of the literature between any of the variants studied
and bladder cancer risk, our primary analysis treated the mi-
nor-variant allele at each locus as the “risk” allele. However,
the assumption that the minor variant is associated with in-
creased risk may not be accurate. We, therefore, also evaluated
other analytic approaches. In particular, we developed a
method for cross-validation. First, we evaluated the main effect
associated with each minor allele in half of the data. We then
reassigned the minor-allele risk status if the main effect of the
minor variant was found to show a negative association with
risk (i.e., OR !1), and we then re-evaluated the risk in the
validation set. To increase the efﬁciency of this testing ap-
proach, we cross-validated 10 randomly selected samples from
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the original data set. The average risk of each SNP in the
validation sets was used to obtain pooled estimates of risk for
each allele and for sums of alleles. The SE (d2) for the allele
effect of each marker is expected to be identical and to show
a covariance of 1/4 across randomly selected subsets. Themean
estimate, , of the allele effect across n replicate samples isb¯
normally distributed with mean m (the per-replicate estimate
of the allele effect) and variance ,
n n n1 2
2 [ j  2  j ]ii ij!n ip1 ip1 i j
where is the variance of the allele effect and is the co-2j jii ij
variance, which is . After simpliﬁcation, the SE of the av-1 2jii4
erage-risk estimate across cross-validation sets is (1/4
, where n is the number of cross-validation replicates.23/[4n])d
For higher-order gene-gene interactions, classiﬁcation and
regression tree (CART) analysis was performed using the
HelixTree Genetics Analysis Software (version 4.1.0, Golden
Helix). CART is a binary recursive-partitioning method that
produces a decision tree to identify subgroups of subjects at
higher risk. Speciﬁcally, the recursive-partitioning algorithm in
HelixTree starts at the ﬁrst node (with the entire data set) and
uses a statistical hypothesis-testing method—formal inference-
based recursive modeling—to determine the ﬁrst locally op-
timal split and each subsequent split of the data set, with mul-
tiplicity-adjusted P values to control tree growth. This process
continues until the terminal nodes have no subsequent statis-
tically signiﬁcant splits or the terminal nodes reach a prespe-
ciﬁed minimum size (at least 10 subjects for each terminal node
in our analysis). The data were divided randomly into a learn-
ing set (90% of the data) and a testing set (10% of the data).
The learning set was used to construct the tree model, and the
testing set was used to internally validate the resulting tree
model.
Results
Characteristics of Subjects
There were a total of 1,484 study subjects recruited
for this study. The population consisted of 1,325 whites
(89.3%), 77 Mexican Americans (5.2%), 67 African
Americans (4.5%), and 15 others (1.0%). Among
whites, there were 696 patients with newly diagnosed,
histologically conﬁrmed bladder cancer and 629 unaf-
fected controls. There was no signiﬁcant age difference
between the cases (63.91  11.17 years) and the con-
trols (62.77 10.50 years) ( ). There were morePp .06
males (78.45%) among the cases than among the con-
trols (72.66%) ( ). As would be predicted, thePp .014
cases had a signiﬁcantly higher percentage of current
(25.29%) and ever smokers (73.55%) than the controls
(8.21% and 53.74%, respectively) ( ). AmongP ! .0001
ever smokers, cases reported signiﬁcantly higher levels
of consumption of cigarettes than controls, as assessed
by computing mean pack-years (42.95 vs. 28.28, P !
)..0001
Risk Associated with Individual SNPs
Since ∼90% of the study subjects were white, we lim-
ited all our analyses to this population. The distributions
of the selected panel of SNPs in the major genes involved
in DNA-repair and cell-cycle–control pathways are sum-
marized in tables 1–4. The allele frequencies of each SNP
in the cases and controls and the corresponding ORs for
the heterozygous and homozygous variant genotypes
and for the combined heterozygote and rare homozygote
genotypes are listed. For main effects of the DNA-repair
genes, individually, only carriers of the variant Asn allele
of XPD, Asp312Asn ( , 95% CI 1.01–1.62),ORp 1.28
and the variant Arg allele of the RAG1, Lys820Arg
( , 95%CI 1.00–1.73), exhibited signiﬁcantlyORp 1.32
increased risks for bladder cancer (tables 1–4). For the
cell-cycle–control genes, a protective effect was found
for carriers of at least one rare allele of the p53 intron
3 SNP ( , 95% CI 0.55–0.94) (table 4). TheORp 0.72
other selected SNPs in the cell-cycle–control pathway
did not show signiﬁcant main effects for bladder cancer
risk (table 4). With consideration of the borderline CIs
and multiple comparisons performed, the impact of any
individual SNP on bladder cancer risk, if it exists, would
be minimal.
Combined Analysis of Multiple SNPs
To test our hypothesis that multiple SNPs in the same
pathway may have an additive effect on bladder cancer
risk, we estimated the combined effect of these SNPs
(table 5). For those genes with multiple SNPs assayed,
only a single SNP was included in this combined analysis
and others were excluded because of linkage disequilib-
rium. The excluded polymorphisms wereXPD (K751Q),
XPC (intron 9 and K939Q), ERCC6 (R1230P),
XRCC1 (R194W), XRCC2 (R188H), XRCC3 (T241M
and 3′ UTR), p53 (intron 6 and R72P), and STK15
(I57V). For the primary analysis, we treated the minor
allele at each locus as the “adverse” allele and tallied
the total number of adverse alleles for each individual.
For the NER pathway, the number of adverse alleles for
each individual ranged from 0 to 10. We categorized
individuals on the basis of the quartile distribution of
the number of adverse alleles in controls, and we set
individuals with fewer than four adverse alleles as the
reference group. Compared with the reference group,
individuals with four ( , 95% CI 1.05–2.20),ORp 1.52
ﬁve to six ( , 95% CI 1.31–2.50), or sevenORp 1.81
or more adverse alleles ( , 95%CI 1.69–3.70)ORp 2.50
exhibited signiﬁcantly higher risks of bladder cancer,
with a signiﬁcant trend of increasing risk with increas-
ing numbers of high-risk alleles (P for trend !.001).
Each additional high-risk allele of the NER pathway
gene was associated with a 21% increase in risk (95%
CI 1.12–1.29) (table 5).
For the HR pathway, using individuals with fewer
than two adverse alleles as the referent group, we noted
a signiﬁcantly elevated association with bladder cancer
risk only for individuals with four or more adverse alleles
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Table 5
Combined Effects of Minor Alleles in the NER, BER, HR, NHEJ, and Cell-
Cycle Pathways
PATHWAY AND NO.
OF MINOR ALLELESa
SUMMATION OF MINOR ALLELES
Case/Control OR (95% CI)b Validationc
NER:
!4 122/186 Reference Reference
4 108/105 1.52 (1.05–2.20) .79 (.54–1.17)
5–6 195/167 1.81 (1.31–2.50) 1.32 (.95–1.84)
7 117/69 2.50 (1.69–3.70) 2.29 (1.52–3.46)
Per allele 1.21 (1.12–1.29) 1.43 (1.27–1.60)
P for trend !.001
HR:
!2 151/171 Reference Reference
2 157/190 .88 (.64–1.20) .97 (.71–1.33)
3 147/140 1.10 (.79–1.54) 1.15 (.81–1.64)
4 147/89 1.70 (1.19–2.43) 1.26 (.85–1.88)
Per allele 1.13 (1.03–1.24) 1.14 (.98–1.32)
P for trend .002
NHEJ:
0 100/101 Reference Reference
1 220/196 1.22 (.86–1.73) 1.29 (.95–1.76)
2 158/186 .91 (.63–1.31) .71 (.51–.98)
3 109/98 1.16 (.77–1.75) 1.08 (.74–1.59)
Per allele .99 (.89–1.11) .94 (.79–1.13)
P for trend .907
BER:
!2 212/199 Reference Reference
3 151/162 .82 (.61–1.12) .60 (.43–.85)
4 113/116 .91 (.65–1.28) .95 (.65–1.39)
5 93/83 1.01 (.70–1.45) 1.45 (.96–2.19)
Per allele .98 (.90–1.07) 1.00 (.87–1.14)
P for trend .924
Cell cycle:
!3 206/174 Reference Reference
3 146/145 .86 (.62–1.18) 1.10 (.78–1.54)
4 120/130 .78 (.56–1.09) .69 (.48–.98)
5 119/131 .79 (.56–1.10) .91 (.64–1.29)
Per allele .94 (.87–1.01) .87 (.77–.98)
P for trend .109
All repair:
!10 74/136 Reference Reference
10–11 109/115 1.59 (1.07–2.37) .64 (.43–.94)
12–14 194/149 2.10 (1.46–3.04) 1.55 (1.10–2.17)
15 111/81 2.31 (1.53–3.51) 2.30 (1.50–3.55)
Per allele 1.11 (1.06–1.16) 1.21 (1.12–1.30)
P for trend !.001
Repair and cell cycle:
!13 86/122 Reference Reference
13–15 152/162 1.22 (.84–1.76) .82 (.58–1.16)
16–17 115/93 1.57 (1.05–2.35) 1.12 (.74–1.68)
18 128/97 1.77 (1.19–2.63) 1.88 (1.27–2.77)
Per allele 1.07 (1.03–1.12) 1.13 (1.05–1.20)
P for trend .002
a Categorized on the basis of the quartile distribution of the number of adverse
alleles in controls.
b Adjusted for age, gender, and smoking status.
c Validation approach deﬁned in text on the basis of 10-fold cross-validation.
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with a similar gene-dosage trend ( , 95% CIORp 1.70
1.19–2.43; P for trend .002) (table 5). Each additional
HR adverse allele was associated with a 1.13-fold in-
crease in risk (95% CI 1.03–1.24). No similar patterns
were observed for the NHEJ, BER, or cell-cycle pathway
polymorphisms (table 5). However, a signiﬁcant gene-
dosage trend was evident when all DNA-repair pathway
genes were combined. Compared with the reference
group (!10 adverse alleles), individuals with 10–11, 12–
14, and 15 adverse alleles had ORs that increased to
1.59 (95% CI 1.07–2.37), 2.10 (95% CI 1.46–3.04),
and 2.31 (95% CI 1.53–3.51), respectively (P for trend
!.001) (table 5). Each additional high-risk allele carried
a 1.11-fold increase in risk (95% CI 1.06–1.16). When
the DNA-repair genes and cell-cycle–control genes were
combined, compared with the reference group of !13
adverse alleles, individuals with 13–15 adverse alleles
had a 1.22-fold increased risk (95% CI 0.84–1.76), in-
dividuals with 16–17 adverse alleles had a 1.57-fold in-
creased risk (95% CI 1.05–2.35), and individuals with
18 adverse alleles had a 1.77-fold increased risk (95%
CI 1.19–2.63). Each additional high-risk allele conferred
a 1.07-fold increase in risk (95% CI 1.03–1.12) (table
5). In comparing the relative contributions of each path-
way, we found the risk conferred by each additional
adverse allele to be the highest for the NER pathway
( , 95% CI 1.12–1.29), intermediate for theORp 1.2
combined DNA-repair pathways ( , 95% CIORp 1.11
1.06–1.16), and lowest for DNA-repair and cell-cycle
pathways ( , 95% CI 1.03–1.12) (table 5).ORp 1.07
These data reafﬁrm that the NER pathway appears to
be the the most signiﬁcant modulator of bladder cancer
risk, with other pathways playing less-prominent roles.
We also developed a statistical method for cross-val-
idation. First, we evaluated the main effect associated
with each minor allele in half of the data set. We then
reassigned the minor-allele risk status if the main effect
of the minor allele was found to show a negative as-
sociation with risk (i.e., OR !1) and then re-evaluated
the risk in the validation set. To increase the efﬁciency
of this testing approach, we used 10 randomly selected
half-sample sets from the original data set to perform
the cross-validation 10 times. The average risk of each
SNP in the validation sets was used to obtain pooled
estimates of risk for each allele and for sums of alleles.
This cross-validation scheme conﬁrmed the signiﬁcant
trend of increasing risk with increasing numbers of high-
risk alleles in the NER pathway, in the entireDNA-repair
pathways, and in DNA-repair plus cell-cycle pathway
genes (table 5, “Validation” column).
Interaction Between Smoking and Genetic Factors
Since smoking is the predominant risk factor for blad-
der cancer, we also stratiﬁed our analyses by smoking
status (table 6). For the NER pathway, individuals with
four, ﬁve to six, and seven or more adverse alleles were
compared with the referent group (fewer than four ad-
verse alleles). There was no evidence of statistically sig-
niﬁcantly increased risks for never smokers (ORp
, 95% CI 0.77–2.72; , 95% CI 0.75–1.45 ORp 1.27
2.13; and , 95% CI 0.72–2.73, respectively,ORp 1.40
for the three strata). However, for ever smokers, signif-
icantly increased risks were found ( , 95% CIORp 1.53
0.99–2.37; , 95% CI 1.50–3.33; andORp 2.23
, 95% CI 2.08–5.48, respectively) (P forORp 3.37
trend !.0001). When we combined the DNA-repair and
cell-cycle–control pathways, there was again evidence of
gene-smoking interaction, with elevated risks evident
only among ever smokers. When all DNA-repair path-
ways were combined, compared with individuals with
!10 adverse alleles, those with 10–11, 12–14, and 15
adverse alleles all exhibited signiﬁcantly increased risks
( , 95% CI 1.23–3.36; , 95% CIORp 2.03 ORp 2.90
1.84–4.59; and , 95% CI 2.08–5.99, re-ORp 3.53
spectively), whereas the risk was not signiﬁcant in any
strata for never smokers (P for trend p .45). Similarly,
when we combined the DNA-repair and cell-cycle genes,
no signiﬁcant association was found in never smokers,
but a higher number of adverse alleles conferred pro-
gressively increased risks in ever smokers (P for trend
!.0001). In the logistic model, the interaction between
ever smoking and the combined variant alleles was sta-
tistically signiﬁcant ( ). Cross-validation veriﬁedP ! .01
that the risks conferred by the adverse alleles were evi-
dent only among ever smokers (table 6, “Validation”
column). A note of caution for the lack of associations
in never smokers: we had approximately twice the num-
ber of smokers as nonsmokers, which limited our sta-
tistical power to detect signiﬁcant associations in never
smokers. Further studies with more never smokers are
needed to conﬁrm these observations.
CART Analysis
CART uses a binary recursive-partitioning method
that identiﬁes subgroups of high-risk subjects and detects
higher-order interactions among a large number of var-
iables. Initial CART analyses for each speciﬁc pathway
identiﬁed the XPD Asp312Asn, RAG1 Lys820Arg, and
p53 intron 3 polymorphisms as the initial splits in their
respective pathways (NER, HR, and cell cycle, respec-
tively) (data not shown), consistent with their main ef-
fects observed by logistic-regression analyses. To further
explore gene-gene and gene-environment interactions,
we performed CART analysis incorporating both the
genetic and smoking-status variables. Figure 1 depicts
the resultant tree structure generated. There was an ini-
tial split on smoking status, conﬁrming that smoking is
the most important risk factor for bladder cancer. Fur-
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Table 6
Combined Effects of Minor Alleles in the NER, DNA-Repair, and Cell-Cycle Pathways,
Stratiﬁed by Smoking Status
PATHWAY, SMOKING STATUS,
AND NO. OF MINOR ALLELESa
SUMMATION OF MINOR ALLELES
Case/Control OR (95% CI)b Validation
NER:
Never:
!4 38/83 Reference Reference
4 26/39 1.45 (.77–2.72) 1.44 (.73–2.84)
5–6 50/87 1.27 (.75–2.13) 1.13 (.66–1.94)
7 22/34 1.40 (.72–2.73) 1.04 (.51–2.14)
P for trend .324
Ever:
!4 56/84 Reference Reference
4 54/60 1.53 (.99–2.37) .51 (.30–.86)
5–6 95/66 2.23 (1.50–3.33) 1.46 (.90–2.35)
7 66/29 3.37 (2.08–5.48) 3.91 (2.16–7.10)
P for trend !.0001
DNA-repair:
Never:
!10 29/62 Reference Reference
10–11 32/53 1.30 (.69–2.42) .90 (.47–1.72)
12–14 43/64 1.43 (.79–2.57) .93 (.52–1.66)
15 23/41 1.20 (.61–2.36) 1.26 (.64–2.51)
P for trend .45
Ever:
!10 45/74 Reference Reference
10–11 77/62 2.03 (1.23–3.36) .52 (.32–.85)
12–14 151/85 2.90 (1.84–4.59) 1.97 (1.28–3.05)
15 88/40 3.53 (2.08–5.99) 3.60 (2.00–6.48)
P for trend !.0001
DNA-repair and cell-cycle:
Never:
!13 35/54 Reference Reference
13–15 35/72 .76 (.42–1.37) .76 (.42–1.37)
16–17 30/37 1.25 (.65–2.38) 1.40 (.70–2.77)
18 26/54 .75 (.40–1.41) .90 (.48–1.68)
P for trend .702
Ever:
!13 51/68 Reference Reference
13–15 117/90 1.73 (1.09–2.73) .81 (.53–1.25)
16–17 85/56 2.03 (1.24–3.35) .97 (.58–1.61)
18 102/43 3.12 (1.87–5.20) 3.18 (1.87–5.40)
P for trend !.0001
a Categorized on the basis of the quartile distribution of the number of adverse alleles
in controls.
b Adjusted for age and gender.
ther inspection of the CART structure suggested distinct
patterns for ever smokers and never smokers. As doc-
umented in previous analyses, the NER gene polymor-
phisms were relevant only in smokers. This was espe-
cially signiﬁcant since four NER SNPs (CCNH V270A,
XPD D312N, ERCC6 M1097V, and RAD23B A249V)
all appeared at early splits during the recursive-parti-
tioning process, indicating a biologically meaningful in-
teraction between NER and smoking. The subgroups
with the highest bladder cancer risk were those smokers
with variant genotypes of CCNH V270A, ERCC6
M1097V, andRAD23B A249V SNPs (node 14 and node
16). In nonsmokers, the three important SNPs were
ADPRT V762A, ATM D1853N, and RAG1 K820R.
These three genes are involved in DSB and BER and play
critical roles in maintaining genomic stability. Table 7
summarizes the risk estimates of all the terminal sub-
groups compared with the subgroups with the least per-
centage of cases (node 1). There was a clear separation
of individuals with varying bladder cancer risks. How-
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Table 7
Risk Estimates of CART Terminal Nodes
Node Genotype of Individuals in Each Node Case Control
Case
Ratea
(%)
Adjusted ORb
(95% CI)
Nonsmokers:
Node 1 ADPRT(M)-ATM(W) 19 68 22 Reference
Node 2 ADPRT(M)-ATM(M)-XRCC3UTR(W) 8 19 30 1.43 (.54–3.79)
Node 4 ADPRT(W)-RAG1(W) 82 146 36 1.97 (1.10–3.50)
Node 8 ADPRT(W)-RAG1(M) 39 38 51 3.68 (1.87–7.25)
Node 12 ADPRT(M)-ATM(M)-XRCC3UTR(M) 8 3 73 8.87 (2.13–36.90)
Smokers:
Node 3 CCNH(W)-XPD312(W)-RAD23(M) 22 43 34 1.72 (.83–3.58)
Node 5 CCNH(M)-ERCC6-1097(M)-RAD23(W)-KU80(M) 5 8 39 2.24 (.65– 7.67)
Node 6 CCNH(M)-ERCC6-1097(W)-NBS1(W) 28 39 42 2.47 (1.22–5.00)
Node 7 CCNH(W)-XPD312(W)-RAD23(W)-RAG1(W) 53 57 48 3.16 (1.67–5.99)
Node 9 CCNH(W)-XPD312(W)-RAD23(W)-RAG1(M)-XRCC3-241(W) 9 8 53 3.88 (1.31–11.45)
Node 10 CCNH(W)-XPD312(M) 158 104 60 5.12 (2.88–9.09)
Node 11 CCNH(M)-ERCC6-1097(W)-NBS1(M) 56 32 64 6.03 (3.08–11.83)
Node 13 CCNH(M)-ERCC6-1097(M)-RAD23(W)-KU80(W) 36 12 75 10.2 (4.43– 23.54)
Node 14 CCNH(M)-ERCC6-1097(M)-RAD23(M)-MUTYH(M) 20 4 83 16.78 (5.10–55.26)
Node 15 CCNH(W)-XPD312(W)-RAD23(W)-RAG1(M)-XRCC3-241(M) 17 2 89 27.84 (5.87–132.13)
Node 16 CCNH(M)-ERCC6-1097(M)-RAD23(M)-MUTYH(W) 35 0 100 N/A
a Case rate is the percentage of cancer patients among all individuals in each node (case/case  control # 100).
b Adjusted for age and gender.
ever, the estimated ORs should be interpreted with
caution, since they were derived from groups identiﬁed
through a data-mining technique applied to the same
data set, and, thus, the level of uncertainty was
underestimated.
To gain insight into the potential mechanism for the
increased cancer risk conferred by these different ge-
notype combinations and to attempt to validate our an-
alytic approach, we next determined genotype-pheno-
type correlations in subjects in all the terminal nodes
(table 8). We applied two widely used methods of de-
tecting latent genomic instability—the mutagen-sensitiv-
ity assay and the comet assay (Hsu et al.1989; Wu et
al. 1998a, 1998b; Schabath et al. 2003). We categorized
the terminal nodes into three groups based on the case
percentage in each node: low-risk group (case percentage
!55%), medium-risk group (case percentage 55%–
75%), and high-risk group (case percentage 175%). In
smokers, there was a signiﬁcant trend of higher numbers
of bleomycin- and BPDE-induced chromosome breaks
(by mutagen-sensitivity assay) and DNA damage (by
comet assay) for individuals in higher-risk subgroups
among cases. The P for the trend was .0348 for bleo-
mycin-induced chromatid breaks, .0036 for BPDE-in-
duced chromatid breaks, and .0397 for BPDE-induced
DNA damage, as measured by the comet assay. There
were no similar patterns in the controls among these
subgroups, suggesting that suboptimal DRC in cases
contributes to their increased cancer risk. Interestingly,
among cases, never smokers exhibited higher bleomycin-
and BPDE-induced chromatid breaks ( andPp .039
.031, respectively) than ever smokers (data not shown),
suggesting that genetic instability plays a more promi-
nent role in predisposing never smokers to bladder can-
cer, whereas, in ever smokers, gene-smoking interaction
plays a central role in bladder cancer etiology.
Discussion
In this study, we have used a multigenic approach to
systematically examine the associations between a panel
of polymorphisms in DNA-repair and cell-cycle genes
and bladder cancer risk. To the best of our knowledge,
this is the most comprehensive multigenic study evalu-
ating the largest number of SNPs. The most signiﬁcant
ﬁnding in this study is that combined analyses of mul-
tiple SNPs in the same or relevant pathways may reveal
otherwise undetectable associations between individual
SNPs with cancer risk. Furthermore, we have shown that
high-risk subgroups selected by the analysis exhibited
high levels of latent genetic instability. Our results sup-
port the concept that genetic polymorphisms can be used
as cancer risk predictors; however, a single polymor-
phism may have little predictive value in risk assessment,
but a more comprehensive pathway-based multigenic
approach combining multiple polymorphisms gives
more-precise delineation of risk groups and may suggest
the future direction of association studies.
There have been many studies reporting associations
between genetic polymorphisms and susceptibility to
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Table 8
Chromosome Breaks and DNA Damage in Terminal Nodes at Smoking Side
RISK
BLEOMYCIN SENSITIVITY BPDE SENSITIVITY BPDE COMET
N
Mean
(SD) P Value N
Mean
(SD) P Value N
Mean
(SD) P Value
Cases:
Low riska 86 .75 (.33) Reference 95 .61 (.28) Reference 74 1.48 (.98) Reference
Medium riskb 168 .84 (.34) .0448 180 .69 (.30) .0323 134 1.77 (1.01) .0347
High riskc 80 .89 (.36) .0101 87 .72 (.31) .0128 73 1.83 (.95) .0295
P for trend .0348 .0036 .0397
Controls:
Low risk 107 .82 (.31) Reference 127 .57 (.27) Reference 108 1.77 (1.78) Reference
Medium risk 82 .84 (.33) .6696 118 .51 (.22) .0688 107 2.04 (2.08) .3075
High risk 11 .83 (.40) .9212 13 .64 (.27) .3748 15 1.73 (1.86) .9355
P for trend .9200 .3339 .9253
a Low risk: nodes 3, 5, 6, 7, and 9.
b Medium risk: nodes 10 and 11.
c High risk: nodes 13, 14, 15, and 16.
common, complex diseases, including cancer. Most of
these studies have used a candidate-gene approach, in-
vestigating one or only a few selected polymorphisms at
a time. Since a complex disease like cancer typically oc-
curs through a multifactorial interplay between many
genetic and environmental factors, the effect of each in-
dividual SNP is unlikely to be substantial. For example,
two of the most intensively studied DNA-repair gene
SNPs, XPD Asp312Asn and Lys751Gln, were hypoth-
esized to modify lung cancer risk, since several pheno-
typic studies suggested that individuals with the variant
Asn or Gln alleles exhibit lower DRC (Spitz et al. 2001;
Stern et al. 2002). Yet, two recent meta-analyses ofXPD
SNPs in lung cancer from nine case-control studies found
that the variant alleles confer only an ∼20% increased
lung cancer risk for either SNP (Hu et al. 2004; Ben-
hamou and Sarasin 2005). Given that the cancer risk is,
at most, modestly altered by individual variants and that
most single studies have used relatively small sample
sizes, it has been estimated that only about a quarter of
previously reported associations were real positive as-
sociations with common diseases (Ioannidis et al. 2001;
Lohmueller et al. 2003).
In our main-effect analysis, theXPDAsp312Asn poly-
morphism was one of only two DNA-repair SNPs that
exhibited a statistically signiﬁcant association with blad-
der cancer risk ( , 95% CI 1.01–1.62). ThisORp 1.28
association is biologically plausible, since the Asn allele
is associated with reduced DRC (Ioannidis et al. 2001),
and a signiﬁcant association of the Asn allele with lung
cancer risk has been observed in a meta-analysis of lung
cancer (Hu et al. 2004; Benhamou and Sarasin 2005).
However, considering the borderline CI (95% CI 1.01–
1.62) and the multiple comparison issue, we cannot rule
out that this individual association was due to type I
error. Moreover, the modest effects of individual variants
would have limited practical value in predicting cancer
risk, highlighting the need for a more comprehensive
approach for association studies.
Our data provide strong evidence for the improvement
of a multigenic approach over the single candidate-gene
approach. We found a signiﬁcant trend of increased risk
with increasing numbers of adverse alleles in the NER
pathway, in the entire DNA-repair pathways, and in the
DNA-repair and cell-cycle pathways combined. The
most signiﬁcant additive effect of multiple polymor-
phisms in a single pathway was observed in the NER
pathway. Individuals with the highest number of adverse
alleles exhibited a 2.50-fold increased bladder cancer
risk (95% CI 1.69–3.70) compared with individuals car-
rying fewer than four high-risk alleles. The difference in
the combined effects of multiple polymorphisms among
each individual pathway may reﬂect the differences in
the contribution of each DNA-repair pathway to bladder
cancer risk. For instance, the NER pathway mainly re-
moves bulky DNA adducts, which are typically gener-
ated from exposure to polycyclic aromatic hydrocarbons
in tobacco smoke. Therefore, the NER pathway would
be expected to play a more signiﬁcant role in repairing
tobacco carcinogen–induced DNA damage, whereas the
other DNA-repair pathways play a less prominent role.
Our CART analysis conﬁrmed and strengthened this
conclusion by showing that NER gene polymorphisms
were selected only in smokers, whereas a few general
maintenance-gene polymorphisms were relevant in
nonsmokers. More interestingly, subsets of individuals
with higher cancer risks were identiﬁed through CART
analysis based on simple combinations of smoking and
genotypes. The simple, intuitive nature of the CART
algorithm may allow rapid identiﬁcation of potential
genetic and environmental interactions when dealing
with large numbers of variables in complex diseases. The
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number of possible interactions grows exponentially as
each additional variable is added. Another strength of
this study is the ability to evaluate changes in levels of
induced genetic damage assessed by three in vitro assays
among subjects in terminal nodes. However, the CART
analysis is a postdata-mining tool and the results should
be interpreted with some degree of caution. External
validation in an independent epidemiology study is war-
ranted to conﬁrm the potential high-risk groups.
Although our primary analysis treated the minor-var-
iant allele at each locus as the risk allele, this assumption
may not be accurate in the absence of knowledge of the
functional consequences of the variants under study. We
therefore evaluated other approaches to the designation
of “at-risk” alleles. For example, if the main effects for
the minor-variant allele exhibited an OR !1 in the initial
multivariate analyses, we assigned the major allele as the
adverse allele. We observed similarly signiﬁcant trends
of increasing risk with increasing numbers of high-risk
alleles, and all associations were stronger (data not
shown), which was not surprising just by the way the
variable was deﬁned. We also performed the data anal-
ysis by reversing the minor allele when OR !1 and
or , and the results were similar to whatP ! .05 P ! .1
we presented in tables 5 and 6, which was also expected
since these criteria affected only a single polymorphism
(p53 intron 3) (data not shown). Choosing the at-risk
allele on the basis of the data set under analysis may
lead to data-driven ﬁndings. There is currently not a
standard way to assign at-risk alleles, and more studies
are needed to develop an optimal way to assign at-risk
alleles.
Matullo et al. (2003) previously found a dose-re-
sponse relationship between the number of adverse al-
leles in DNA-repair gene SNPs and levels of DNA ad-
ducts in peripheral blood cells, suggesting a stepwise
decrease in DRC as the number of adverse alleles in-
creases and lending biological support for analyzing
combined effects of multiple-variant alleles rather than
investigating single SNPs in modulating cancer risk. Our
phenotypic assays also demonstrated that higher-risk
subgroups, as identiﬁed from the CART analysis, ex-
hibited higher chromosome breaks and DNA damage
(table 8), thereby providing additional biological plau-
sibility and validity to our approach.
Although we tried to be as inclusive as possible in our
selection of genes and SNPs, the selection criteria was
based on potential functional SNPs in genes with higher
possibilities of being related to cancer risk. A more com-
prehensive pathway-based approach—for example, se-
lecting tagging SNPs in most key genes in a deﬁned path-
way—would offer more convincing evidence for the
relevance of the evaluated pathway in cancer risk. Nev-
ertheless, this is the most comprehensive study to date
to use a multigenic approach to analyze multiple genetic
polymorphisms in DNA-repair and cell-cycle genes in
bladder cancer risk. Our results suggest that individuals
with higher numbers of variants in DNA-repair genes
are at an increased risk for bladder cancer, verifying the
importance of taking a pathway-based approach to im-
prove the resolution of the risk-assessment process. This
study not only is important for bladder cancer risk as-
sessment but is also applicable to risk assessment of
many complex diseases incorporating low-penetrance
genes. These data conﬁrm the notion that the future of
risk assessment for multigenic complex diseases needs
to move beyond analysis of single polymorphisms.
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